ACAA2 and metabolic dysfunction-associated steatotic liver disease: In conclusion, CAND1 is a negative regulator of NAFLD, which exerts its action by restraining the assembly of Cullin1, FBXO42 and ACAA2 complexes and inhibiting ubiquitinated degradation of ACAA2 (Fig. 9).